Phase 3 Recruiting Industry
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…
Sponsor: Genmab
NCT ID: NCT06191744
Locations: - UCSF Fresno /ID# 264712 — Fresno, California
- Scripps Mercy Hospital /ID# 265393 — San Diego, California
- Sansum Clinic Research /ID# 261596 — Santa Barbara, California
+ 55 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free surviv…
Sponsor: BeiGene
NCT ID: NCT05100862
Locations: - Ucsf Fresno University of California San Francisco Fresno — Fresno, California
- Kaiser Permanente Southern California — Irvine, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
+ 46 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Locations: - City of Hope (Adults and Pediatrics) — Duarte, California
- University of California San Diego Moores Cancer Center (Adults only) — La Jolla, California
- Loma Linda University Medical Center (Adults only) — Loma Linda, California
+ 37 more sites in the U.S.
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Locations: - Research Site — Anchorage, Alaska
- Research Site — Phoenix, Arizona
- Research Site — Clovis, California
+ 29 more sites in the U.S.
Phase 3 Recruiting Industry
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymph…
Sponsor: Celgene
NCT ID: NCT06911502
Locations: - Local Institution - 0225 — Birmingham, Alabama
- Infirmary Cancer Care — Mobile, Alabama
- Alaska Oncology and Hematology — Anchorage, Alaska
+ 28 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05139017
Locations: - Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175) — Glendale, Arizona
- Beverly Hills Cancer Center ( Site 0184) — Beverly Hills, California
- Bass Medical Group ( Site 0166) — Walnut Creek, California
+ 21 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Locations: - Pacific Cancer Medical Center, Inc — Anaheim, California
- TOI Clinical Research — Cerritos, California
- Stanford School of Medicine-Cancer Clinical Trials Office — Palo Alto, California
+ 16 more sites in the U.S.
Phase 3 Recruiting Industry
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Sponsor: Soligenix
NCT ID: NCT06470451
Locations: - Medical Dermatology Specialists — Phoenix, Arizona
- Mayo Clinic — Scottsdale, Arizona
- Therapeutics Clinical Research — San Diego, California
+ 14 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (here…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06074588
Locations: - UCLA Hematology/Oncology - Santa Monica ( Site 0023) — Los Angeles, California
- Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0001) — Jacksonville, Florida
- Mid Florida Hematology and Oncology Center ( Site 0005) — Orange City, Florida
+ 12 more sites in the U.S.
Phase 3 Recruiting Industry
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Saf…
Sponsor: Acrotech Biopharma Inc.
NCT ID: NCT06072131
Locations: - University of California, San Francisco Fresno — Clovis, California
- University of California, Los Angeles Hem/ Onc Clinical Research Unit, Suite 600 — Santa Monica, California
- University of Colorado School of Medicine — Aurora, Colorado
+ 8 more sites in the U.S.
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or margina…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06149286
Locations: - David Geffen School of Medicine at UCLA — Los Angeles, California
- Boca Raton Clinical Research (BRCR) Global — Plantation, Florida
- Indiana University and Comprehensive Cancer Center — Indianapolis, Indiana
+ 5 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The researchers are doing this study to find out whether a very low dose of radiation therapy (VLDRT) is an effective treatment for people with follicular lymphoma (FL) or marginal zone lymphoma (MZL) and works as well as the standard dose…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07029217
Locations: - Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
+ 4 more sites in the U.S.